# Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

> **NCT00103935** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** Exenatide LAR
- **DRUG:** Exenatide LAR

## Key facts

- **NCT ID:** NCT00103935
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103935, "Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00103935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*